Literature DB >> 25082816

Dynamics of leukemia stem-like cell extinction in acute promyelocytic leukemia.

Benjamin Werner1, Robert E Gallagher2, Elisabeth M Paietta2, Mark R Litzow3, Martin S Tallman4, Peter H Wiernik5, James L Slack6, Cheryl L Willman7, Zhuoxin Sun8, Arne Traulsen1, David Dingli9.   

Abstract

Many tumors are believed to be maintained by a small number of cancer stem-like cells, where cure is thought to require eradication of this cell population. In this study, we investigated the dynamics of acute promyelocytic leukemia (APL) before and during therapy with regard to disease initiation, progression, and therapeutic response. This investigation used a mathematical model of hematopoiesis and a dataset derived from the North American Intergroup Study INT0129. The known phenotypic constraints of APL could be explained by a combination of differentiation blockade of PML-RARα-positive cells and suppression of normal hematopoiesis. All-trans retinoic acid (ATRA) neutralizes the differentiation block and decreases the proliferation rate of leukemic stem cells in vivo. Prolonged ATRA treatment after chemotherapy can cure patients with APL by eliminating the stem-like cell population over the course of approximately one year. To our knowledge, this study offers the first estimate of the average duration of therapy that is required to eliminate stem-like cancer cells from a human tumor, with the potential for the refinement of treatment strategies to better manage human malignancy. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25082816      PMCID: PMC4184925          DOI: 10.1158/0008-5472.CAN-14-1210

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  48 in total

1.  Quantitative real-time RT-PCR analysis of PML-RAR alpha mRNA in acute promyelocytic leukemia: assessment of prognostic significance in adult patients from intergroup protocol 0129.

Authors:  Robert E Gallagher; Beow Y Yeap; Wanli Bi; Kenneth J Livak; Nike Beaubier; Sreenivas Rao; Clara D Bloomfield; Frederick R Appelbaum; Martin S Tallman; James L Slack; Cheryl L Willman
Journal:  Blood       Date:  2002-12-05       Impact factor: 22.113

2.  Molecular analysis and clinical outcome of adult APL patients with the type V PML-RARalpha isoform: results from intergroup protocol 0129.

Authors:  J L Slack; C L Willman; J W Andersen; Y P Li; D S Viswanatha; C D Bloomfield; M S Tallman; R E Gallagher
Journal:  Blood       Date:  2000-01-15       Impact factor: 22.113

Review 3.  Evolution of the cancer stem cell model.

Authors:  Antonija Kreso; John E Dick
Journal:  Cell Stem Cell       Date:  2014-03-06       Impact factor: 24.633

4.  Growth rates and responses to treatment in human myelomatosis.

Authors:  J R Hobbs
Journal:  Br J Haematol       Date:  1969-06       Impact factor: 6.998

5.  Statistical theory of cooperative binding to proteins. The Hill equation and the binding potential.

Authors:  H D Heck
Journal:  J Am Chem Soc       Date:  1971-01-13       Impact factor: 15.419

Review 6.  The theory of APL.

Authors:  F Piazza; C Gurrieri; P P Pandolfi
Journal:  Oncogene       Date:  2001-10-29       Impact factor: 9.867

7.  Allometric scaling of metabolic rate from molecules and mitochondria to cells and mammals.

Authors:  Geoffrey B West; William H Woodruff; James H Brown
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-19       Impact factor: 11.205

Review 8.  Acute promyelocytic leukemia: where does it stem from?

Authors:  D Grimwade; T Enver
Journal:  Leukemia       Date:  2004-03       Impact factor: 11.528

9.  Use of an X-linked human neutrophil marker to estimate timing of lyonization and size of the dividing stem cell pool.

Authors:  E S Buescher; D W Alling; J I Gallin
Journal:  J Clin Invest       Date:  1985-10       Impact factor: 14.808

10.  All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol.

Authors:  Martin S Tallman; Janet W Andersen; Charles A Schiffer; Frederick R Appelbaum; James H Feusner; William G Woods; Angela Ogden; Howard Weinstein; Lois Shepherd; Cheryl Willman; Clara D Bloomfield; Jacob M Rowe; Peter H Wiernik
Journal:  Blood       Date:  2002-08-15       Impact factor: 22.113

View more
  14 in total

Review 1.  Targeting of leukemia-initiating cells in acute promyelocytic leukemia.

Authors:  Ugo Testa; Francesco Lo-Coco
Journal:  Stem Cell Investig       Date:  2015-04-29

2.  Retinoic acid and 6-formylindolo(3,2-b)carbazole (FICZ) combination therapy reveals putative targets for enhancing response in non-APL AML.

Authors:  Rodica P Bunaciu; Robert J MacDonald; Holly A Jensen; Feng Gao; Xin Wang; Lynn Johnson; Jeffrey D Varner; Andrew Yen
Journal:  Leuk Lymphoma       Date:  2018-12-20

3.  Retinoid Chemoprevention: Who Can Benefit?

Authors:  Rodica P Bunaciu; Andrew Yen
Journal:  Curr Pharmacol Rep       Date:  2015-04-15

4.  The Cancer Stem Cell Fraction in Hierarchically Organized Tumors Can Be Estimated Using Mathematical Modeling and Patient-Specific Treatment Trajectories.

Authors:  Benjamin Werner; Jacob G Scott; Andrea Sottoriva; Alexander R A Anderson; Arne Traulsen; Philipp M Altrock
Journal:  Cancer Res       Date:  2016-02-01       Impact factor: 12.701

5.  Arsenic trioxide promoting ETosis in acute promyelocytic leukemia through mTOR-regulated autophagy.

Authors:  Tao Li; Ruishuang Ma; Yan Zhang; Hongdan Mo; Xiaoyan Yang; Shaoshan Hu; Lixiu Wang; Valerie A Novakovic; He Chen; Junjie Kou; Yayan Bi; Bo Yu; Shaohong Fang; Jinghua Wang; Jin Zhou; Jialan Shi
Journal:  Cell Death Dis       Date:  2018-01-23       Impact factor: 8.469

6.  Replicative cellular age distributions in compartmentalized tissues.

Authors:  Marvin A Böttcher; David Dingli; Benjamin Werner; Arne Traulsen
Journal:  J R Soc Interface       Date:  2018-08       Impact factor: 4.118

7.  6-Formylindolo(3,2-b)Carbazole (FICZ) Modulates the Signalsome Responsible for RA-Induced Differentiation of HL-60 Myeloblastic Leukemia Cells.

Authors:  Rodica P Bunaciu; Holly A Jensen; Robert J MacDonald; Dorian H LaTocha; Jeffrey D Varner; Andrew Yen
Journal:  PLoS One       Date:  2015-08-19       Impact factor: 3.240

Review 8.  Current Challenges in Glioblastoma: Intratumour Heterogeneity, Residual Disease, and Models to Predict Disease Recurrence.

Authors:  Hayley P Ellis; Mark Greenslade; Ben Powell; Inmaculada Spiteri; Andrea Sottoriva; Kathreena M Kurian
Journal:  Front Oncol       Date:  2015-11-16       Impact factor: 6.244

9.  A stochastic model of myeloid cell lineages in hematopoiesis and pathway mutations in acute myeloid leukemia.

Authors:  Frank Jäkel; Oliver Worm; Sascha Lange; Roland Mertelsmann
Journal:  PLoS One       Date:  2018-10-01       Impact factor: 3.240

10.  Differentiation of leukemic blasts is not completely blocked in acute myeloid leukemia.

Authors:  Anupriya Agarwal; William J Bolosky; David B Wilson; Christopher A Eide; Susan B Olson; Guang Fan; Brian J Druker
Journal:  Proc Natl Acad Sci U S A       Date:  2019-11-21       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.